zh-twzhen
zh-twzhen

The Company’s 2025Q2 consolidated financial statements have been approved by the Board of Directors

2024

Date

Title

2024-08-27

Oneness Biotech Co., Ltd. receives a Japanese patent titled “TOPICAL FORMULATION FOR PROMOTING WOUND HEALING” on Fespixon cream (Research code: ON101).

>
2024-08-15

Oneness Biotech Co., Ltd. receives a Philippine patent titled “TOPICAL FORMULATION FOR PROMOTING WOUND HEALING” on Fespixon cream (Research code: ON101).

>
2024-08-12

Announcement of change to the financial officer, accounting officer, acting spokesperson and corporate governance officer of the company.

>
2024-08-12

Oneness announces the resolution of the Board of Directors on the Record Date of Capital Increase for the issuance of Restricted Employee Shares in 2023.

>
2024-08-12

The Company’s 2024Q2 consolidated financial statements have been approved by the Board of Directors

>
2024-08-07

Fespixon has passed the preliminary review by the National Healthcare Security Administration of China

>
2024-08-06

Fespixon, the new drug in treatment of diabetic foot ulcers has been approved by Indonesia BPOM and the drug license will be collected

>
2024-08-02

Announcement of the date of the Company’s board of directors meeting for the Second Quarter of 2024 Consolidated Financial Reports

>
2024-07-25

Fespixon has been included in CSE Expert consensus on wound treatment of diabetic foot ulcer (2024). The health economics analysis supports its cost-effectiveness.

>
2024-07-22

News-Oneness Biotech Licenses Fespixon® to China Resources for 20 Years in US$33.5M Deal Body

>
2024-07-22

The EU MDR application of Bonvadis for acute and chronic wounds and scar management has been accepted by EU Notified Body for QMS and product certification.

>
2024-07-21

Oneness and Microbio (Shanghai) have entered into an exclusive agreement of Fespixon commercialization with China Resources Double Crane Pharmaceutical Co., Ltd.

>
2024-07-09

Announced The Board of Directors’ resolution of 2024 that the related matters of ex-dividend.

>
2024-07-02

Fespixon is included in the “DAROC Clinical Practice Guidelines For Type 2 Diabetes Care 2022” (2024 update)

>
2024-06-28

With its medical device clearance by the FDA for partial-thickness wounds, Oneness has decided to discontinue ON101CLCT04 Ph3 clinical trial in the US

>